Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
复制标题
DOI：
10.1053/euhj.1998.1201
复制
发表时间：
1998-12-01
影响因子：
39.3
通讯作者：
Dargie, HJ
中科院分区：
文献类型：
--
作者：
Newby, DE;McDonagh, T;Dargie, HJ
目的评价新型中性内肽酶抑制剂坎多沙曲尔对接受血管紧张素转换酶抑制治疗的轻中度慢性心力衰竭患者的运动能力、临床状态和生活质量的影响。在为期4周的每周运动测试的单盲安慰剂“磨合”阶段之后，患者接受了双盲随机试验，在接下来的84天里接受依安多曲利(每天两次，100毫克)或安慰剂。然后每28天对患者进行重新评估。在110名随机分组的患者中，56名接受坎多沙利治疗，54名接受安慰剂治疗。在研究期间，与安慰剂组相比，坎多沙曲组的平均总锻炼时间提高了34.1%S(P=0.02：95%可信区间：5.1%至63.0%)。两组患者的功能分级、临床状态和生活质量评分均无明显变化。结论在接受血管紧张素转换酶抑制剂治疗的慢性心力衰竭患者中，坎多沙曲利可改善患者的运动能力。
Aims To assess the effect of candoxatril, a novel neutral endopeptidase inhibitor, on exercise capacity, clinical status and quality of life in patients with mild to moderate chronic heart failure receiving angiotensin converting enzyme inhibition.Methods and Results Patients were recruited from 16 centres throughout the United Kingdom. Following a 4-week single-blind placebo 'run-in' phase of weekly exercise tests, patients underwent double-blind randomization to receive either eandoxatril (100 mg twice daily) or placebo for the next 84 days. Patients were then reassessed every 28 days.Of 110 patients randomized, 56 received candoxatril and 54 placebo. Over the study period, the overaII improvement in mean total exercise time in the candoxatril group in comparison to the placebo group was 34.1 s (P=0.02: 95% confidence interval: 5.1 to 63.0). There were no significant changes in functional class, clinical status or quality of life scores between the two groups. There was a trend for a small reduction in blood pressure in the candoxatril group.Conclusion Candoxatril confers an improvement in exercise capacity in patients with chronic heart failure who are receiving, maintenance angiotensin converting enzyme inhibitor therapy.